+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Staccato alprazolam, an inhaled medication, in people aged 12 years and older who experience stereotypical prolonged seizures. The study aims to compare a single dose of Staccato alprazolam with a placebo in quickly stopping a seizure within 90 seconds and preventing further seizures for up to 2 hours after treatment. Participants are randomly assigned to receive either one dose of Staccato alprazolam or a matching placebo by inhalation in this double-blind study. This single-dose treatment is given during the outpatient treatment period, and participants are monitored closely to assess seizure control and safety. During the study, participants will have their seizures evaluated for treatment success within 90 seconds and for any recurrence up to 6 hours after dosing. Researchers will also monitor respiratory events and seizure frequency. Participants will have regular assessments, including safety follow-up visits extending up to 19 weeks after treatment, to ensure thorough monitoring of effects and any adverse events.

Age: 12Years +All GendersPhase 3
183 locations
O

Actively Recruiting

Researchers are evaluating how the drug cenobamate affects healthcare resource use for adults with epilepsy who have uncontrolled focal onset seizures. This observational, retrospective study compares medical resource use before and after patients start cenobamate as an additional therapy because previous anti-seizure medications were not effective or tolerable. Data from medical charts of 200 patients across 10 sites in 5 countries will be collected and analyzed. The study focuses on adult patients who began treatment with cenobamate as adjunctive therapy according to approved guidelines. Patients included have uncontrolled focal seizures despite 2 to 5 prior anti-seizure medications and have at least 6 months of data before starting cenobamate and 12 months of data afterward. This retrospective chart review gathers real-world data without altering patient treatment. Participants medical records will be reviewed for healthcare resource use related to epilepsy, including hospital visits, emergency care, medication use, surgeries, and phone or virtual contacts over a 12-month period before and after starting cenobamate. Researchers will also assess safety data and how concomitant anti-seizure medications change. The study is conducted under data protection regulations and will provide insights into the impact of cenobamate on managing uncontrolled focal seizures.

Age: 18Years +All Genders
10 locations